Fundz

Gallant closes $18 million Series B to advance its stem cell therapies for pets, led by Digitalis Ventures.

PRIVATEJun 30, 2025

Amount Raised

$18 Million

Round Type

Series B

San DiegoOtherBiotechnologyHealth CareTherapeutics

Investors

NovaQuest Capital ManagementHill Creek PartnersBold CapitalDigitalis Ventures

Description

Gallant, an animal health biotechnology company, successfully closed its $18 million Series B financing round. The funding, led by Digitalis Ventures, will accelerate the commercial rollout of its lead product targeting Feline Chronic Gingivostomatitis. This funding also supports a pipeline of therapies for other common diseases in pets. Gallant aims to address the underlying issues rather than merely managing symptoms.

Who to call at Gallant, and when

A new round usually means Gallant is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Gallant raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Gallant, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Gallant. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Gallant

Location

10865 Road to the Cure, Ste 101

San Diego, California, United States

About

Gallant is a regenerative medicine company pioneering veterinary therapies that restore health at the source. We’re developing a pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies to address chronic conditions in dogs and cats—including feline chronic gingivostomatitis (FCGS), osteoarthritis, chronic kidney disease, and atopic dermatitis. Our first product, based on a proprietary uterine-derived stem cell platform, is on track for conditional FDA approval in 2026. Led by industry pioneers in veterinary regenerative medicine, Gallant combines science, purpose, and compassion to help pets live healthier, more vibrant lives.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Gallant raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsValentine W., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Gallant's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Gallant raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.